1. Home
  2. Topics
  3. Takeda completes the evaluation of RaQualia’s compound

Topics

Takeda completes the evaluation of RaQualia’s compound

RaQualia Pharma Inc. (“RaQualia”) announced that under the agreement with Takeda Pharmaceutical Company Limited (“Takeda”), Takeda has completed their evaluation of the effectiveness of a RaQualia compound targeting a non-disclosed indication in the gastroenterology therapeutic area.

 

After completion of this evaluation Takeda has decided to not pursue further development of the compound. Upon this decision, RaQualia will receive all data that Takeda generated during the evaluation.

 

RaQualia remains confident in the potential medical use of this class of compounds and will continue to pursue such possibilities and explore potential partnerships.

 

The financial forecasts for FY2018 (January 1, 2018 to December 31, 2018) will not be affected by this announcement.

 

 

####

Page Top

Corporate Information
CEO Message
Company Overview
Vision, Management Principle and Culture
Quality Policy
Corporate Governance
Business Model
Origins of Our Corporate Name and Logo
Access
Press Release
Research & Development
Collaboration
Partnering in Research
What are Research Tools?
Research Tool Licensing
Product Information
Anidulafungin
Ziprasidone
Dalbavancin
Potassium-Competitive Acid Blocker
5-HT4 Partial Agonist
5-HT2B Antagonist
Motilin Receptor Agonist
Licensing Status
Shareholder and Investor Information
Vision, Management Principle and Culture
Corporate Governance
Outline of Securities Matters
IR Library
IR Calendar
Disclaimer
IR Related News
Understanding RaQualia Pharma! RaQualia FAQ
RaQualia's History
What does RaQualia Pharma do?
How Does RaQualia Earn Revenues?
What About Dividends?
What are RaQualia's strengths?
What Does the Future Hold for RaQualia Pharma?
Contributions to Society
Corporate Contributions
Contributions to the Community
Press Release
Topics